Article Text

Download PDFPDF

410 Clinical characteristics of systemic lupus erythrematosus in an egyptian population: a descriptive retrospective case series
  1. B Mohammed Medhat Ali1,
  2. T El Hadidi2,
  3. K El Hadidi1,
  4. A Youssri3,
  5. D Attia1,
  6. M Eissa1,
  7. EG Nehal1,
  8. AEB Noha1,
  9. W Abd el Rahman1,
  10. L Maged1,
  11. S Ghoniem1,
  12. M Shaaban1,
  13. R El Refai1,
  14. N Sobhy1 and
  15. F Talaat1
  1. 1Cairo University, Rheumatology and Rehabilitation, Cairo, Egypt
  2. 2Armed Forces, Rheumatology, Cairo, Egypt
  3. 3Cairo University, Rheumatology and Rehabiliation, Cairo, Egypt


Background and aims Systemic lupus erythrematosus (SLE) is an autoimmune disease with a myriad of manifestations, that could vary among different ethnic and racial groups.

Aim of the study: To study the prevalence of various manifestations of SLE in an Egyptian population.

Methods Information in this study was derived from the medical records of SLE patients, who followed up in 2 private clinics in Cairo from January 1980 to June 2016.

Results This study included 1109 SLE patients, of which 114 (10.3%) were males and 995 were females (89.7%). Age of onset showed a mean of 26±11.19 years, and the mean of disease duration was 48.78±58.46 months. The most common manifestations were synovitis (76.7%), malar rash (48.5%), leukopenia (45.7%), and photosensitivity (45.6%). At least one of the antiphospholipid antibodies was present in 41.8% of the patients, with thromboembolic manifestations and/or recurrent fetal loss present in 18.3% of the patients. Neuropsychiatric manifestations were evident in 7.8% of the patients, with seizures being the most common neuropsychiatric manifestation, present in 4%. 33.1% of the patients had nephritis, which succeeded the onset of the disease by a mean duration of 20±21.3 months. 29.3% of the patients continued follow up and received induction therapy according to the guidelines at the time of presentation (cyclophosphamide: 11.8%, mycophenolate mofetyl: 7.6%, and azathioprine: 9.8%). Of which, 24.9% continued follow up and achieved partial (9.9%) and complete (15%) remission.

Conclusions Synovitis and malar rash were the most common manifestations in our study. Secondary antiphospholipid was present in 18.3% of the patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.